<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJH</journal-id>
<journal-id journal-id-type="hwp">spajh</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Hosp Palliat Care</journal-id>
<journal-title>American Journal of Hospice and Palliative Medicine®</journal-title>
<issn pub-type="ppub">1049-9091</issn>
<issn pub-type="epub">1938-2715</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1049909111423094</article-id>
<article-id pub-id-type="publisher-id">10.1177_1049909111423094</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Role of Haloperidol in Palliative Medicine</article-title>
<subtitle>An Update</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Prommer</surname>
<given-names>Eric</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1049909111423094">1</xref>
<xref ref-type="corresp" rid="corresp1-1049909111423094"/>
</contrib>
<aff id="aff1-1049909111423094"><label>1</label>Mayo Clinic College of Medicine, Mayo Clinic Hospital</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1049909111423094">Eric Prommer, 5777 East Mayo Boulevard, Room SpC 209, Scottsdale, Phoenix, AZ 85054, USA Email: <email>prommer.eric@mayo.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>29</volume>
<issue>4</issue>
<fpage>295</fpage>
<lpage>301</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia. Awareness of the role dopamine plays in many symptoms in palliative care, such as nausea, vomiting, and delirium, has led to the use of dopamine antagonists such as haloperidol for the treatment of these symptoms in the palliative care setting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic insufficiency. Haloperidol is extensively metabolized in the liver, with CYP3A4 the chief cytochrome oxidase responsible for metabolism. This article will review the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine. There will be an examination of the evidence base for the use of haloperidol in palliative medicine.</p>
</abstract>
<kwd-group>
<kwd>haloperidol</kwd>
<kwd>nausea</kwd>
<kwd>delirium</kwd>
<kwd>dopamine</kwd>
<kwd>QT interval</kwd>
<kwd>dosing</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1049909111423094">
<title>Introduction</title>
<p>Haloperidol has long been considered the standard representative of the butyrophenone class of drugs, which are considered important neuroleptic compounds.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111423094">1</xref>
</sup> Haloperidol was discovered in 1958, during the process of improving the analgesic effect of the opioid pethidine.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111423094">1</xref>
</sup> Modification of pethidine, with the incorporation of a butyrophenone group, led to a drug with short-term analgesic effects but with powerful sedative effects.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111423094">1</xref>
</sup> Similarities to chloropromazine were drawn and eventually the drug called haloperidol, named for the halogenated substitutes incorporated into the molecule, was introduced into psychiatric therapy. Originally used for the treatment of schizophrenia, uses of haloperidol have evolved from an antipsychotic to an important agent in palliative care for symptom control. The drug has been used for symptom management in palliative medicine where the blockade of dopamine receptors is beneficial and as such, haloperidol has been used for delirium and nausea and vomiting. This article will focus on the pharmacology, pharmacokinetics, and current uses of haloperidol in palliative medicine, with a closer look at the database for its efficacy in symptom control.</p>
<p>A phenyl-piperidinyl-butyrophenone, haloperidol has the chemical name 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone.<sup>
<xref ref-type="bibr" rid="bibr2-1049909111423094">2</xref>
</sup> Haloperidol has a piperidine ring and possesses the classic butryophenone chain as its basic structure (containing the ketone group seen in the <xref ref-type="fig" rid="fig1-1049909111423094">Figure 1</xref>). The presence of the hydroxyl group enhances the binding of haloperidol to the dopamine receptor.<sup>
<xref ref-type="bibr" rid="bibr3-1049909111423094">3</xref>
</sup> The butyrophenone chain appears also to be essential for dopamine binding as any shortening of the chain leads to reduced binding.<sup>
<xref ref-type="bibr" rid="bibr3-1049909111423094">3</xref>
</sup>
</p>
<fig id="fig1-1049909111423094" position="float">
<label>Figure 1.</label>
<caption>
<p>Structure of Haloperidol.</p>
</caption>
<graphic xlink:href="10.1177_1049909111423094-fig1.tif"/>
</fig>
<sec id="section2-1049909111423094">
<title>Pharmacodynamics</title>
<p>Haloperidol is a potent dopamine antagonist with a strong affinity for the D<sub>2</sub> dopamine receptor (<italic>K<sub>i</sub>
</italic> of 1.4 nmol/L.).<sup>
<xref ref-type="bibr" rid="bibr4-1049909111423094">4</xref>
</sup> Haloperidol has a weak serotonin binding (<italic>K<sub>i</sub>
</italic> is &gt;1000 for all serotonin receptor subtypes except for the 5-hydroxytryptamine (5HT)<sub>2a</sub> receptor which reportedly can be as low as 25 and as high as 200).<sup>
<xref ref-type="bibr" rid="bibr4-1049909111423094">4</xref>
</sup> Haloperidol has minimal interaction with opioid, muscarinic, and histamine receptors.<sup>
<xref ref-type="bibr" rid="bibr5-1049909111423094">5</xref>
</sup> It does have some affinity with the α-1 adrenergic receptor with affinities ranging from 19 to 40 nmol/L.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111423094">4</xref>
</sup>
</p>
</sec>
<sec id="section3-1049909111423094">
<title>Formulation</title>
<p>Haloperidol is available in tablet, oral solution, and intravenous (IV) solution forms. The oral tablet is available in 0.5, 1, 2, 5, 10, and 20 mg formulations and an oral solution of a 2 mg/mL concentration. The parenteral formulations include a solution for intramuscular (IM) and IV injection (5 mg/mL).</p>
</sec>
<sec id="section4-1049909111423094">
<title>Compatibility</title>
<p>Haloperidol, when administered by IV or subcutaneous routes, is compatible with opioids such as diamorphine, hydromorphone, and morphine. It is also compatible with other drugs such as cyclizine (when given in dextrose, 5%), tramadol, hyoscine butylbromide, ketamine, and midazolam. The mixture of haloperidol and dexamethasone is incompatible and they should be given separately. Haloperidol should not be given with methotrimeprazine together in an infusion. There is also incompatibility when haloperidol is mixed with hyoscine butylbromide (not available in the United States).<sup>
<xref ref-type="bibr" rid="bibr6-1049909111423094">6</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section5-1049909111423094">
<title>Pharmacology and Routes of Administration</title>
<p>Haloperidol has been administered orally, IV infusion, IM, subcutaneously, topically, and rectally.</p>
</sec>
<sec id="section6-1049909111423094">
<title>Oral</title>
<p>Haloperidol has an oral bioavailability of 60% to 70%. Time to peak concentration can vary with a wide range of values for the time to peak plasma concentration (<italic>T</italic>
<sub>max</sub>; 2-6 hours).<sup>
<xref ref-type="bibr" rid="bibr7-1049909111423094">7</xref>
</sup> The half-life ranges from 15 to 37 hours. Haloperidol has a volume of distribution of 18 L/kg. There is a linear correlation between the dose of haloperidol and the plasma and blood concentrations. Haloperidol has extensive protein binding with a free fraction in the plasma of only 7.5% to 11%. There is wide variation in area under the curve and clearance among individuals. Haloperidol concentrations reach steady state around 1 week. Reduced haloperidol is more readily detected after oral administration, which suggests that a first-pass mechanism is responsible for its production.</p>
<sec id="section7-1049909111423094">
<title>Intravenous Route</title>
<p>After IV administration, the time to <italic>T</italic>
<sub>max</sub> is 5 to 15 minutes with serum haloperidol concentrations declining biphasically. The terminal elimination life (t<sub>1/2</sub>) is 14.1 to 26.2 hours.<sup>
<xref ref-type="bibr" rid="bibr8-1049909111423094">8</xref>
</sup> The volume of distribution ranges from 9.5 to 21.7 L/kg, with plasma or serum clearance calculated to be 0.39 to 0.708 L/h per kg (6.5-11.8 mL/min per kg), respectively.<sup>
<xref ref-type="bibr" rid="bibr8-1049909111423094">8</xref>
</sup>
</p>
</sec>
<sec id="section8-1049909111423094">
<title>Intramuscular Route</title>
<p>After IM administration, <italic>T</italic>
<sub>max</sub> is 20 minutes in healthy individuals or 33.8 minutes in patients with schizophrenia. The mean t<sub>1/2</sub> is 20.7 hours and bioavailability following IM administration.<sup>
<xref ref-type="bibr" rid="bibr9-1049909111423094">9</xref>
</sup>
</p>
</sec>
<sec id="section9-1049909111423094">
<title>Subcutaneous Route</title>
<p>There is no pharmacokinetic data on the use of subcutaneous haloperidol.</p>
</sec>
<sec id="section10-1049909111423094">
<title>Topical</title>
<p>Haloperidol has been evaluated in a pilot study form for the treatment of chemotherapy-related nausea and vomiting. There is no information of pharmacokinetics associated with this route.<sup>
<xref ref-type="bibr" rid="bibr10-1049909111423094">10</xref>
</sup>
</p>
</sec>
<sec id="section11-1049909111423094">
<title>Rectal Haloperidol Absorption</title>
<p>There is no information on rectal pharmacokinetics of haloperidol. The haloperidol analog droperidol, when given rectally as an IV solution, has a short duration of action (2-4 hours).<sup>
<xref ref-type="bibr" rid="bibr11-1049909111423094">11</xref>
</sup>
</p>
</sec>
<sec id="section12-1049909111423094">
<title>Metabolism</title>
<p>Haloperidol is extensively metabolized in the liver with only 1% excreted unmetabolized.<sup>
<xref ref-type="bibr" rid="bibr12-1049909111423094">12</xref>
</sup> The chief pathway for metabolism is the cytochrome oxidase pathway with CYP3A4 the chief isoform involved.<sup>
<xref ref-type="bibr" rid="bibr13-1049909111423094">13</xref>
</sup> The metabolites of haloperidol include <italic>p</italic>-fluorobenzoylpropionic acid,4-(chlorophenyl)-4-hydroxypiperidine,<sup>
<xref ref-type="bibr" rid="bibr12-1049909111423094">12</xref>
</sup> reduced haloperidol, pyridinium metabolites, and haloperidol glucuronide.<sup>
<xref ref-type="bibr" rid="bibr14-1049909111423094">14</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr15-1049909111423094">15</xref>
</sup> Glucuronide metabolites are excreted in the bile and can be metabolized by bacteria in the gut with reabsorbtion back systemically, a process called enterohepatic circulation.<sup>
<xref ref-type="bibr" rid="bibr12-1049909111423094">12</xref>
</sup> In the case of haloperidol, this glucuronide metabolite is not affected by bacteria.<sup>
<xref ref-type="bibr" rid="bibr12-1049909111423094">12</xref>
</sup> After glucuronidation, there is further back oxidation and reduction to reduced haloperidol.<sup>
<xref ref-type="bibr" rid="bibr15-1049909111423094">15</xref>
</sup> There is also <italic>N</italic>-dealkylation to a pyridium metabolite which may have toxicity.<sup>
<xref ref-type="bibr" rid="bibr16-1049909111423094">16</xref>
</sup> The glucuronidated metabolite is inactive. Haloperidol is also an inhibitor as well as an inducer of CYP2D6.</p>
<p>Metabolites such as reduced haloperidol also can act as a substrate of CYP3A4 and can also inhibit CYP2D6.</p>
</sec>
</sec>
<sec id="section13-1049909111423094">
<title>Dosing in Special Populations</title>
<sec id="section14-1049909111423094">
<title>Hepatic Disease</title>
<p>The hepatic extraction ratio for haloperidol is 0.3:0.7, indicating a moderately extractable drug which in turn means that haloperidol is subject to hepatic blood flow, protein binding, and intrinsic enzyme activity.<sup>
<xref ref-type="bibr" rid="bibr17-1049909111423094">17</xref>,<xref ref-type="bibr" rid="bibr18-1049909111423094">18</xref>
</sup> It is thus potentially affected by liver disease and dose modification may be necessary.</p>
</sec>
<sec id="section15-1049909111423094">
<title>Renal Disease</title>
<p>There is no need for alteration of drug dosing in renal insufficiency.</p>
</sec>
<sec id="section16-1049909111423094">
<title>Drug Interactions</title>
<p>Drugs that may affect the disposition of haloperidol include inducers of CYP3A4, such as carbamezepine,<sup>
<xref ref-type="bibr" rid="bibr19-1049909111423094">19</xref>
</sup> phenobarbital,<sup>
<xref ref-type="bibr" rid="bibr20-1049909111423094">20</xref>
</sup> and phenytoin,<sup>
<xref ref-type="bibr" rid="bibr20-1049909111423094">20</xref>
</sup> which can lower the levels of haloperidol. Antidepressants such as fluoxetine, venlaflaxine, nefazodone, and fluvoxamine, through the inhibition of CYP3A4, can increase haloperidol levels.<sup>
<xref ref-type="bibr" rid="bibr21-1049909111423094">21</xref>
<xref ref-type="bibr" rid="bibr22-1049909111423094"/><xref ref-type="bibr" rid="bibr23-1049909111423094"/>–<xref ref-type="bibr" rid="bibr23-1049909111423094">23</xref>
</sup> Citalopram and sertraline do not affect haloperidol levels.<sup>
<xref ref-type="bibr" rid="bibr24-1049909111423094">24</xref>,<xref ref-type="bibr" rid="bibr25-1049909111423094">25</xref>
</sup> Sedative hypnotics such as alprazolam increases the levels of haloperidol but lorazepam has no effect.<sup>
<xref ref-type="bibr" rid="bibr26-1049909111423094">26</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section17-1049909111423094">
<title>Adverse Effects</title>
<sec id="section18-1049909111423094">
<title>Extrapyramidal Side Effects</title>
<p>The high affinity of haloperidol for the dopamine receptor predisposes toward a higher risk of extrapyramidal side effects (EPSs). There is little literature regarding the occurrence of EPS with the doses of haloperidol used in palliative care. In a study comparing haloperidol with lorazepam for the treatment of delirium,<sup>
<xref ref-type="bibr" rid="bibr27-1049909111423094">27</xref>
</sup> average haloperidol doses of 2.8 mg/d were associated with a low incidence of EPS and unassociated with the need to cease therapy. In that study, there were more adverse effects (non-EPS) that occurred in the lorazepam arm of the study. In the study, the development of adverse effects in all patients receiving lorazepam led to the ultimate termination of the lorazepam arm before study completion and the haloperidol arm was continued successfully. Given the limited data, it appears that low doses of haloperidol can be given for the treatment of delirium without excessive incidences of EPS.</p>
</sec>
<sec id="section19-1049909111423094">
<title>QT Interval Prolongation</title>
<p>One recent review examined the role of haloperidol on the development of corrected QT (QTc) prolongation and torsades de pointes (TdP).<sup>
<xref ref-type="bibr" rid="bibr28-1049909111423094">28</xref>
</sup> This involved information from medical databases and the Food and Drug Administration. The time period ranged from 1997 to 2008 and the report found 70 cases of QTc prolongation and/or TdP. Of these cases, 54 reported TdP, with 80% preceded by QTc prolongation, and nearly all cases had prolongation times of &gt;450 ms. Three patients experienced sudden cardiac arrest. Highly prevalent in the cases of QTc prolongation and TdP were additional risk factors such as preexisting heart disease, electrolyte imbalance, concomitant proarrhythmic drugs, and mechanical ventilation. The study investigators found a relationship to dose of haloperidol, where patients receiving low doses of haloperidol (low cumulative doses &lt;2 mg), having no risk factors for prolonged QTc or TdP, and a normal QTc on baseline electrocardiogram, being able to safely be given IV haloperidol in the hospital setting. There is no information of the incidence of QTc and TdP in patients receiving oral haloperidol.</p>
</sec>
<sec id="section20-1049909111423094">
<title>Seizures</title>
<p>Both first- and second-generation antipsychotics can lower the seizure threshold, but there are differences among the drugs comprising each group in the ability to lower the seizure threshold. Among the first-generation antipsychotics, of which haloperidol is included, it is the phenothiazine class of antipsychotic (such as chloropromazine) that carries the greatest risk of seizures, with an incidence<sup>28</sup> of approximately 1.2%.<sup>
<xref ref-type="bibr" rid="bibr28-1049909111423094">28</xref>
</sup> Several reviews indicate that haloperidol is a typical antipsychotic whose use is associated with a relatively low risk of seizures.<sup>
<xref ref-type="bibr" rid="bibr29-1049909111423094">29</xref>,<xref ref-type="bibr" rid="bibr30-1049909111423094">30</xref>
</sup>
</p>
</sec>
<sec id="section21-1049909111423094">
<title>Neuroleptic Malignant Syndrome</title>
<p>Neuroleptic malignant syndrome (NMS) is a neurologic emergency which is associated with neuroleptic use. It is believed that the syndrome results from dopamine receptor blockade.<sup>
<xref ref-type="bibr" rid="bibr31-1049909111423094">31</xref>
</sup> Risk factors for the development of NMS include high doses of neuroleptics, rapid dose escalation, parenteral route of administration, coexisting conditions such as agitation and dehydration.<sup>
<xref ref-type="bibr" rid="bibr32-1049909111423094">32</xref>
</sup> Reports from the psychiatric literature suggest an NMS prevalence<sup>
<xref ref-type="bibr" rid="bibr33-1049909111423094">33</xref>
</sup> of 0.07% to 2.2%. Neuroleptic malignant syndrome has been reported most commonly with haloperidol and can occur with oral and parenteral administration. Neuroleptic malignant syndrome has occurred after doses under 10 mg/d but is usually seen with patients experiencing a rapid increase in dose, parenteral route administration, and administration for associated conditions such as extreme agitation, psychomotor excitement, refusal of food, and rapid weight loss. The typical presentation occurs at doses of 15 mg/d or more. Neuroleptic malignant syndrome can occur at any time during therapy.<sup>
<xref ref-type="bibr" rid="bibr34-1049909111423094">34</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section22-1049909111423094">
<title>Clinical Indications: Delirium</title>
<p>The use of haloperidol for delirium is advocated by most experts, but the evidence base for this recommendation is weak. This is most likely due to concerns about the use of placebo arms in patient having delirium. Studies that have evaluated haloperidol for delirium have been hampered by small sample size, difficulties with randomization or blinding, poor classification of delirium subtypes, inequalities in study groups, and methodological differences in dose titration.</p>
<sec id="section23-1049909111423094">
<title>Haloperidol Versus Risperidone</title>
<p>Han and Kim<sup>
<xref ref-type="bibr" rid="bibr35-1049909111423094">35</xref>
</sup> compared risperidone and haloperidol for the treatment of delirium in the intensive care setting and included a wide variety of patients having cancer, cardiovascular disease as well as stroke, renal failure, and postoperative patients. This was a prospective, randomized, double-blind study, where screening for delirium was performed with the Confusion Assessment Method and the Delirium Rating scale (DRS) and diagnosis was determined with the Structured Clinical Interview for <italic>Diagnostic and Statistical Manual of Mental Disorders</italic> (Third Edition Revised [<italic>DSM-III-R</italic>]). Responses to treatment were evaluated daily (same time daily) by a blinded investigator. Responses to therapy were also measured by the Memorial Delirium Assessment scale. A total of 24 patients with DRS scores of 13 and above were randomized to a regimen of 0.75 mg (haloperidol) or 0.5 mg (risperidone) tablets twice a day, with dose adjustments made during the 7-day study. The average dose required to control delirium was 1.71 mg in the haloperidol group and 1.02 mg in the risperidone group. There were significant decreases in both groups with respect to delirium scores as measured by the Memorial Delirium Assessment scale (<italic>P</italic> &lt; .05). There were no advantages for either drug when assessing the rapidity of response. Only 1 patient in the haloperidol arm had akathisia.</p>
</sec>
<sec id="section24-1049909111423094">
<title>Critical Care Setting</title>
<p>Skrobik and coworkers<sup>
<xref ref-type="bibr" rid="bibr36-1049909111423094">36</xref>
</sup> compared olanzapine to haloperidol in the management of delirium in the critical care setting. They randomized a surgical patient population in the intensive care unit (on even/odd day basis) to receive olanzapine or haloperidol by oral route or by nasogastric tube, if necessary. Haloperidol was begun at a dose of 2.5 to 5 mg every 8 hours and olanzpine was 5 mg/d. Patients who were older than 60 years received a 50% dose reduction of the proposed starting dose. Subsequent titration was based on clinical judgment. Delirium intensity as measured by the Delirium Index and use of benzodiazepines as rescue medications were also measured during the 5 days of the study. Of the 1009 patients admitted to the intensive care unit during the study period, 214 were diagnosed with delirium. After excluding patients with gastrointestinal dysfunction, a total of 103 patients entered the study. Both groups of patients experienced improvement with no differences in the decrease of the Delirum Index. In both the groups, the need for benzodiazepines decreased likewise. Extrapyramidal side effect was noted in the haloperidol group (6 patients) but not in the olanzapine group.</p>
</sec>
<sec id="section25-1049909111423094">
<title>AIDS</title>
<p>Breitbart and coworkers,<sup>27</sup> in an effort to determine the optimal agent for delirium in hospitalized patients with AIDS, compared haloperidol, chlorpromazine, and lorazepam in a prospective, randomized, double-blind trial. In total, 244 patients were included in the study and were identified as having delirium using the DRS (score &gt; 13) as well as by meeting <italic>DSM-III-R</italic>. Patients meeting entry criteria were randomized to receive haloperidol, chlorpromazine, or lorazepam. Initial doses of patients were haloperidol 0.25 mg orally or 0.125 mg IM, chlorpromazine 10 mg orally, or lorazepam 0.5 mg orally or 0.25 mg IM. The dose was doubled if there was no response (asleep, calm, or no hallucinating) with doses titrated upward until target symptoms were reached. If a successful dose was found, a maintenance dose of one half of the 24-hour requirement to achieve reversal of delirium was given and started twice daily. The results showed that both antipsychotic arms showed improvement in delirium scores as measured by the DRS, but there was no change in scores in the lorazepam group. Cognitive function as measured by the Mini-Mental Status Examination also improved in patients receiving the antipsychotics with improvement being clinically significant in the chlorpromazine arm.</p>
</sec>
<sec id="section26-1049909111423094">
<title>Nausea and Vomiting</title>
<p>There have been no randomized controlled trials evaluating haloperidol for nausea and vomiting.<sup>37</sup> One case series has been published with a focus on nausea and vomiting in terminally ill patients who did not have bowel obstruction.<sup>
<xref ref-type="bibr" rid="bibr38-1049909111423094">38</xref>
</sup> In the studies that were done there was no systematic evaluation of baseline symptoms or outcomes.<sup>
<xref ref-type="bibr" rid="bibr37-1049909111423094">37</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section27-1049909111423094">
<title>ABHR Formulation: Topical/Rectal Haloperidol</title>
<p>Lorazepam,diphenhydramine, haloperidol, metoclopramide (ABHR) topical gel or rectal suppositories, which contain lorazepam, diphenhydramine, haloperidol, and metoclopramide, have been used for the management of refractory nausea and vomiting in hospice patients.<sup>
<xref ref-type="bibr" rid="bibr38-1049909111423094">38</xref>
</sup> The formulation has also been used to manage restlessness, agitation, or anxiety in hospice patients. The dose of haloperidol in the gel formulation of ABHR ranges from 1 to 2 mg. As a suppository, ABHR contains haloperidol in the range of 0.25 to 1 mg. There has been no study evaluating ABHR topical gel or rectal suppositories in a prospective manner.</p>
<sec id="section28-1049909111423094">
<title>Bowel Obstruction</title>
<p>Haloperidol is often used for malignant bowel obstruction<sup>
<xref ref-type="bibr" rid="bibr39-1049909111423094">39</xref>
</sup> but has not been compared with other antiemetics for the management of nausea associated with bowel obstruction.</p>
</sec>
<sec id="section29-1049909111423094">
<title>Hiccups</title>
<p>Two small case series suggest efficacy for haloperidol in the management of hiccups.<sup>
<xref ref-type="bibr" rid="bibr40-1049909111423094">40</xref>,<xref ref-type="bibr" rid="bibr41-1049909111423094">41</xref>
</sup> Routes of administration included IM haloperidol and haloperidol given per nasogastric tube. TJ,</p>
</sec>
<sec id="section30-1049909111423094">
<title>Terminal Sedation</title>
<p>Terminal sedation is often used at the end of life when symptoms such as pain, nausea, myoclonus, restlessness, or respiratory distress have not responded to conventional management, or urgent intervention is needed due to imminent death of the patient or symptoms are severe.</p>
<p>Haloperidol has been evaluated for terminal sedation. In a study<sup>
<xref ref-type="bibr" rid="bibr42-1049909111423094">42</xref>
</sup> of 251 patients, 70 required sedation for refractory symptoms such as agitated delirium, dyspnea, severe pain, and insomnia, and haloperidol was used in 35 patients (50%). Halperidol use did not influence survival time, and surveys of staff and family indicated that haloperidol was an effective agent for terminal sedation. No dosage guidelines were provided in this study.</p>
</sec>
</sec>
<sec id="section31-1049909111423094">
<title>Schedule of Administration</title>
<sec id="section32-1049909111423094">
<title>Route Changes</title>
<p>When switching from the oral to IV route and vice versa, the IV route is one half that of the oral route, based on the bioavailability of the oral dose.<sup>
<xref ref-type="bibr" rid="bibr43-1049909111423094">43</xref>
</sup>
</p>
</sec>
<sec id="section33-1049909111423094">
<title>Dosing of Haloperidol in Delirium</title>
<p>Overall, low doses of haloperidol can be successful in managing the agitation or hallucinations associated with delirium.<sup>
<xref ref-type="bibr" rid="bibr44-1049909111423094">44</xref>
</sup> The optimal dosing method for delirium is not yet known. Some experts advocate aggressive titration of target symptoms such as agitation and hallucinations, using 0.5 to 1 mg haloperidol (oral, IV, IM, and subcutaneous) administered hourly according to the clinical response.<sup>
<xref ref-type="bibr" rid="bibr45-1049909111423094">45</xref>
</sup> Clinical guidelines<sup>
<xref ref-type="bibr" rid="bibr46-1049909111423094">46</xref>
</sup> also recommend stratification of the severity of delirium with dosing based on the results. In patients with mild-to-moderate delirium, recommendations are for haloperidol to be started at low doses (0.5 mg [orally] 2-3 times a day), with titration to obtain an effect. There are no data on the success of this method of management. Parenteral haloperidol is recommended for severe delirium with dose modifications being made based on age. Recommendations for higher parenteral doses are 1 to 2 mg in young patients and lower (0.25-0.5 mg) in elderly patients (≥60 years), to be repeated after 1 to 2 hours as needed until decreased agitation is observed.<sup>
<xref ref-type="bibr" rid="bibr47-1049909111423094">47</xref>
</sup> Only 1 study has examined aggressive titration for the management of delirium. Akechi and coworkers<sup>
<xref ref-type="bibr" rid="bibr48-1049909111423094">48</xref>
</sup> used a 30-minute interval titration protocol in patients with cancer, with doses given orally or parenterally according to feasibility (0.5 mg IM/IV or 0.75 mg orally for 3 doses, 1 mg IM/IV or 1.5 mg orally for 3 doses, 2 mg IV/IM or 3 mg orally for 3 doses, and 5 mg IV/IM for 3 doses). When using this dosing protocol, an average dose of 6 mg was needed to control delirium (range 5-11 mg/d). Half of the patients required &lt;5 mg on the first day to achieve control of target symptoms such as agitation. In this method of dosing, the haloperidol dose on subsequent days was based on the total dose of the previous day. This regimen suggests that the total dose of the drug on the first day is very important in the management of delirium. New information suggests that other factors can influence haloperidol dosing in delirium. Recent data suggest that health care professional distress can lead to increased doses.<sup>
<xref ref-type="bibr" rid="bibr44-1049909111423094">44</xref>
</sup> Delivery of haloperidol by the subcutaneous route is used by many palliative care practitioners with equal efficacy.<sup>
<xref ref-type="bibr" rid="bibr49-1049909111423094">49</xref>
</sup>
</p>
</sec>
<sec id="section34-1049909111423094">
<title>Nausea and Vomiting</title>
<p>Despite the absence of clinical trial data, physicians could start haloperidol at a dose of 0.5 mg every 4 to 6 hours by IV or subcutaneous route. More frequent dosing may be limited by adverse effects such as EPS. The data on topical haloperidol suggest that 2 mg topically every 6 hours was effective for chemotherapy-related nausea and vomiting.<sup>
<xref ref-type="bibr" rid="bibr10-1049909111423094">10</xref>
</sup>
</p>
</sec>
<sec id="section35-1049909111423094">
<title>Bowel Obstruction</title>
<p>The recommendations for dosing with haloperidol in malignant bowel obstruction come from expert opinion only and suggest doses of 5 to 15 mg/d subcutaneously either as bolus or as continuous infusion.<sup>
<xref ref-type="bibr" rid="bibr50-1049909111423094">50</xref>
</sup>
</p>
</sec>
<sec id="section36-1049909111423094">
<title>Dosing in Terminal Sedation</title>
<p>The haloperidol dose for terminal sedation has not been studied in a prospective manner, but expert opinion suggests intermittent dosing of haloperidol as follows: 0.5 to 5 mg orally or subcutaneously every 2 to 4 hours or 1 to 5 mg bolus IV or subcutaneously, then continuous infusion either subcutaneously or IV at 5 mg/d; usual maintenance dose, 5 to 15 mg/d is a reasonable dosing regimen.<sup>
<xref ref-type="bibr" rid="bibr51-1049909111423094">51</xref>
</sup>
</p>
</sec>
<sec id="section37-1049909111423094">
<title>Pharmacoeconomics</title>
<p>The average cost of haloperidol is as follows: 1 mg, $8.04 for #100; 5 mg, $17.83 for #100; and 5 mg/mL, $8.69 for a box of #10.</p>
</sec>
</sec>
<sec id="section38-1049909111423094">
<title>Conclusion</title>
<p>Haloperidol, the prototypical compound of the butyrophenone neurolpetic class of drug, is a high-affinity dopamine antagonist, whose potent antagonism for the dopamine receptor has led to its use in several dopamine-mediated symptoms which occur in palliative medicine, such as delirium, nausea, and vomiting. Listed as 1 of the 25 important drugs in palliative care, haloperidol can be administered by multiple routes and can be given without dose alteration in the setting of both renal and hepatic compromise. Haloperidol is extensively metabolized in the liver by CYP3A4. The high affinity of haloperidol for the dopamine receptor increases the risk of adverse effects such as EPS. The risk of EPS increases with dose but the incidence appears to be low at doses under 2 mg/d. Corrected QT prolongation becomes a risk when haloperidol is given in high-risk clinical situations such as preexisting heart disease, electrolyte imbalance, concomitant proarrhythmic drugs, and mechanical ventilation. Clinical trials evaluating haloperidol for delirium suggest that haloperidol is as effective as risperidone in patients with cancer-related delirium comparable with olanzapine in the management of delirium in the critical care setting and more effective than placebo for delirium in AIDS. It is also more effective than lorazepam for the management of delirium in AIDS and less likely to produce adverse effects than lorazepam. Controlled trials are lacking in the use of haloperidol for nausea and vomiting in advanced cancer and bowel obstruction associated with nausea and vomiting. There is little evidence for the use of haloperidol in other symptoms such as hiccups. The gaps in the evidence base remain opportunities for future research in the evidence-base development of this potent symptom control agent.</p>
</sec>
</body>
<back>
<ref-list>
<title>Reference</title>
<ref id="bibr1-1049909111423094">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cecilio</surname>
<given-names>LM.</given-names>
</name>
</person-group>
<article-title>The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice</article-title>. <source>Brain Res Bull</source>. <year>2009</year>;<volume>79</volume>(<issue>2</issue>):<fpage>130</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr2-1049909111423094">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reed</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>The crystal and molecular structure of haloperidol, a potent psychotropic drug</article-title>. <source>Acta Crystallogr Sect B</source>. <year>1973</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1886</fpage>–<lpage>1890</lpage>.</citation>
</ref>
<ref id="bibr3-1049909111423094">
<label>3</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Ablordeppey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Glennon</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Pharmacophore models for 1 receptor binding</article-title>. In: <source>Sigma Receptors</source>. <year>2007</year>;<fpage>71</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr4-1049909111423094">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Shayegan</surname>
<given-names>DK</given-names>
</name>
</person-group>. <article-title>The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice</article-title>. <source>J Clin Psychiatry</source>. <year>2003</year>;<volume>64</volume>(<issue>suppl 19</issue>):<fpage>6</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr5-1049909111423094">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schotte</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>PFM</given-names>
</name>
<name>
<surname>Gommeren</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding</article-title>. <source>Psychopharmacology</source>. <year>1996</year>;<volume>124</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr6-1049909111423094">
<label>6</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dickman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>J</given-names>
</name>
</person-group>. <source>The Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care</source>. <publisher-loc>New york, NY</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr7-1049909111423094">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishizaki</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Pharmacokinetics of haloperidol: an update</article-title>. <source>Clin Pharmacokinet</source>. <year>1999</year>;<volume>37</volume>(<issue>6</issue>):<fpage>435</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr8-1049909111423094">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holley</surname>
<given-names>FO</given-names>
</name>
<name>
<surname>Magliozzi</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Stanski</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Lombrozo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hollister</surname>
<given-names>LE</given-names>
</name>
</person-group>. <article-title>Haloperidol kinetics after oral and intravenous doses</article-title>. <source>Clin Pharmacol Ther</source>. <year>1983</year>;<volume>33</volume>(<issue>4</issue>):<fpage>477</fpage>–<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr9-1049909111423094">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaffer</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Shahid</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Javaid</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Dysken</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients</article-title>. <source>J Clin Psychopharmacol</source>. <year>1982</year>;<volume>2</volume>(<issue>4</issue>):<fpage>274</fpage>.</citation>
</ref>
<ref id="bibr10-1049909111423094">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bleicher</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bhaskara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huyck</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials</article-title>. <source>J Support Oncol</source>. <year>2008</year>;<volume>6</volume>(<issue>1</issue>):<fpage>27</fpage>.</citation>
</ref>
<ref id="bibr11-1049909111423094">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Southam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Pharmacokinetics of droperidol in healthy volunteers following intravenous infusion and rectal administration from an osmotic drug delivery module</article-title>. <source>Pharm Res</source>. <year>1992</year>;<volume>9</volume>(<issue>5</issue>):<fpage>694</fpage>–<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr12-1049909111423094">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forsman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Öhman</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>On the pharmacokinetics of haloperidol</article-title>. <source>Nord J Psychiatr</source> <year>1974</year>;<volume>28</volume>(<issue>6</issue>):<fpage>441</fpage>–<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr13-1049909111423094">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Silverstone</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Coutts</surname>
<given-names>RT</given-names>
</name>
</person-group>. <article-title>Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol</article-title>. <source>Cell Mol Neurobiol</source>. <year>1997</year>;<volume>17</volume>(<issue>2</issue>):<fpage>227</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr14-1049909111423094">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Terauchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kagemoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sekine</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Use of antisera in the isolation of human specific conjugates of haloperidol</article-title>. <source>Xenobiotica</source>. <year>1989</year>;<volume>19</volume>(<issue>7</issue>):<fpage>781</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr15-1049909111423094">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Someya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shibasaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>INABA</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction</article-title>. <source>J Clin Psychopharmacol</source>. <year>1992</year>;<volume>12</volume>(<issue>3</issue>):<fpage>169</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr16-1049909111423094">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramanyam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pond</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Eyles</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Whiteford</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Fouda</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Castagnoli</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1991</year>;<volume>181</volume>(<issue>2</issue>):<fpage>573</fpage>–<lpage>578</lpage>.</citation>
</ref>
<ref id="bibr17-1049909111423094">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Kunka</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rudolph</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Perel</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients</article-title>. <source>J Clin Pharmacol</source>. <year>1995</year>;<volume>35</volume>(<issue>2</issue>):<fpage>202</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr18-1049909111423094">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blaschke</surname>
<given-names>TF</given-names>
</name>
</person-group>. <article-title>Protein binding and kinetics of drugs in liver diseases</article-title>. <source>Clin Pharmacokinet</source> <year>1997</year>; <volume>2</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr19-1049909111423094">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jann</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Ereshefsky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Saklad</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of carbamazepine on plasma haloperidol levels</article-title>. <source>J Clin Psychopharmacol</source>. <year>1985</year>;<volume>5</volume>(<issue>2</issue>):<fpage>106</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr20-1049909111423094">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linnoila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Viukari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vaisanen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Auvinen</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Effect of anticonvulsants on plasma haloperidol and thioridazine levels</article-title>. <source>Am J Psychiatry</source>. <year>1980</year>;<volume>137</volume>(<issue>7</issue>):<fpage>819</fpage>–<lpage>821</lpage>.</citation>
</ref>
<ref id="bibr21-1049909111423094">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniel</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Randolph</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jaskiw</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Coadministration of fluvoxamine increases serum: concentrations of haloperidol</article-title>. <source>J Clin Psychopharmacol</source>. <year>1994</year>;<volume>14</volume>(<issue>5</issue>):<fpage>340</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr22-1049909111423094">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbhaiya</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>UA</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Breuel</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Midha</surname>
<given-names>KK</given-names>
</name>
</person-group>. <article-title>Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol</article-title>. <source>J Clin Psychopharmacol</source>. <year>1996</year>;<volume>16</volume>(<issue>1</issue>):<fpage>26</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr23-1049909111423094">
<label>23</label>
<citation citation-type="book">
<collab collab-type="author">Physician’s Desk Reference</collab>. <edition>52 ed</edition>. <publisher-loc>Montvale, NJ</publisher-loc>: <publisher-name>Medical Economics Company</publisher-name>; <year>1998</year>:<fpage>3037</fpage>–<lpage>3041</lpage>.</citation>
</ref>
<ref id="bibr24-1049909111423094">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>KY</given-names>
</name>
</person-group>. <article-title>A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia</article-title>. <source>J Clin Psychopharmacol</source>. <year>1998</year>;<volume>18</volume>(<issue>5</issue>):<fpage>399</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr25-1049909111423094">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syv-Lahti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Taiminen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>SaarijSrvi</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients</article-title>. <source>J Int Med Res</source> <year>1997</year>;<volume>25</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr26-1049909111423094">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mahal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gaertner</surname>
<given-names>HJ</given-names>
</name>
</person-group>. <article-title>Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis</article-title>. <source>Pharmacopsychiatry</source>. <year>1992</year>;<volume>25</volume>:<fpage>273</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr27-1049909111423094">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breitbart</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Marotta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients</article-title>. <source>Focus</source>. <year>2005</year>;<volume>3</volume>(<issue>2</issue>):<fpage>333</fpage>.</citation>
</ref>
<ref id="bibr28-1049909111423094">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hedges</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jeppson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Antipsychotic medication and seizures: a review</article-title>. <source>Drugs Today</source>. <year>2003</year>;<volume>39</volume>(<issue>7</issue>):<fpage>551</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr29-1049909111423094">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remick</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Fine</surname>
<given-names>SH</given-names>
</name>
</person-group>. <article-title>Antipsychotic drugs and seizures</article-title>. <source>J Clin Psychiatry</source>. <year>1979</year>;<volume>40</volume>(<issue>2</issue>):<fpage>78</fpage>.</citation>
</ref>
<ref id="bibr30-1049909111423094">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pisani</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Oteri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Di Raimondo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Di Perri</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Effects of psychotropic drugs on seizure threshold</article-title>. <source>Drug Saf</source>. <year>2002</year>;<volume>25</volume>(<issue>2</issue>):<fpage>91</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr31-1049909111423094">
<label>31</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Benzer</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Neuroleptic malignant syndrome</article-title>. <year>2002</year>;<fpage>19</fpage>:<year>2004</year>. <ext-link ext-link-type="uri" xlink:href="http://www.emedicine.com/EMERG/topic339.html">http://www.emedicine.com/EMERG/topic339.html</ext-link>.</citation>
</ref>
<ref id="bibr32-1049909111423094">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellamy</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kane-Gill</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Falcione</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Seybert</surname>
<given-names>AL</given-names>
</name>
</person-group>. <article-title>Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol</article-title>. <source>J Trauma</source>. <year>2009</year>;<volume>66</volume>(<issue>3</issue>):<fpage>954</fpage>–<lpage>958</lpage>.</citation>
</ref>
<ref id="bibr33-1049909111423094">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coulter</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Neuropsychiatric complications of commonly used palliative care drugs</article-title>. <source>Postgrad Med</source>  <year>2008</year>;<volume>84</volume>(<issue>989</issue>):<fpage>121</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr34-1049909111423094">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Neuroleptic malignant syndrome: review of response to therapy</article-title>. <source>Arch Intern Med</source>. <year>1989</year>;<volume>149</volume>(<issue>9</issue>):<fpage>1927</fpage>–<lpage>1931</lpage>.</citation>
</ref>
<ref id="bibr35-1049909111423094">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YK</given-names>
</name>
</person-group>. <article-title>A double-blind trial of risperidone and haloperidol for the treatment of delirium</article-title>. <source>Psychosomatics</source>. <year>2004</year>;<volume>45</volume>(<issue>4</issue>):<fpage>297</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr36-1049909111423094">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skrobik</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Bergeron</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dumont</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gottfried</surname>
<given-names>SB</given-names>
</name>
</person-group>. <article-title>Olanzapine vs haloperidol: treating delirium in a critical care setting</article-title>. <source>Intensive Care Med</source>. <year>2004</year>;<volume>30</volume>(<issue>3</issue>):<fpage>444</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr37-1049909111423094">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Critchley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Plach</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Grantham</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review</article-title>. <source>J Pain Symptom Manage</source>. <year>2001</year>;<volume>22</volume>(<issue>2</issue>):<fpage>631</fpage>.</citation>
</ref>
<ref id="bibr38-1049909111423094">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lichter</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Results of antiemetic management in terminal illness</article-title>. <source>J Palliat Care</source>. <year>1993</year>;<volume>9</volume>(<issue>2</issue>):<fpage>19</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr39-1049909111423094">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ventafridda</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ripamonti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Caraceni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spoldi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Messina</surname>
<given-names>L</given-names>
</name>
<name>
<surname>De Conno</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>The management of inoperable gastrointestinal obstruction in terminal cancer patients</article-title>. <source>Tumori</source>. <year>1990</year>;<volume>76</volume>(<issue>4</issue>):<fpage>389</fpage>–<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr40-1049909111423094">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dromerick</surname>
<given-names>AW</given-names>
</name>
</person-group>. <article-title>Intractable hiccups during stroke rehabilitation</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1998</year>;<volume>79</volume>(<issue>6</issue>):<fpage>697</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr41-1049909111423094">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ives</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Weart</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Bloch</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Treatment of intractable hiccups with intramuscular haloperidol</article-title>. <source>Am J Psychiatry</source>. <year>1985</year>;<volume>142</volume>(<issue>11</issue>):<fpage>1368</fpage>–<lpage>1368</lpage>.</citation>
</ref>
<ref id="bibr42-1049909111423094">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiu</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Lue</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CY</given-names>
</name>
</person-group>. <article-title>Sedation for refractory symptoms of terminal cancer patients in Taiwan</article-title>. <source>J Pain Symptom Manage</source>. <year>2001</year>;<volume>21</volume>(<issue>6</issue>):<fpage>467</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr43-1049909111423094">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vella-Brincat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Macleod</surname>
<given-names>AD</given-names>
</name>
</person-group>. <article-title>Haloperidol in palliative care</article-title>. <source>Palliat Med</source>. <year>2004</year>;<volume>18</volume>(<issue>3</issue>):<fpage>195</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr44-1049909111423094">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hui</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Yennurajalingam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bruera</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Neuroleptic dose in the management of delirium in patients with advanced cancer</article-title>. <source>J Pain Symptom Manage</source>. <year>2010</year>;<volume>39</volume>(<issue>2</issue>):<fpage>186</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr45-1049909111423094">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breitbart</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Delirium in the Terminally</article-title>. <source>Handb Psychiatry Palliat Med</source>. <year>2000</year>;<fpage>75</fpage>.</citation>
</ref>
<ref id="bibr46-1049909111423094">
<label>46</label>
<citation citation-type="web">
<collab collab-type="author">Canadian Coalition for Seniors’ Mental Health</collab>, <article-title>National guidelines for seniors' mental health: the assessment and treatment of delirium</article-title>. <source>Canadian Coalition for Seniors’ Mental Health, National guidelines 2010</source>. <ext-link ext-link-type="uri" xlink:href="http://www.ccsmh.ca/en/guidelinesusers.cfm">http://www.ccsmh.ca/en/guidelinesusers.cfm</ext-link>. <comment>Accessed November 3, 2008</comment>.</citation>
</ref>
<ref id="bibr47-1049909111423094">
<label>47</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Lipowski</surname>
<given-names>ZJ</given-names>
</name>
</person-group>. <source>Delirium: Acute Confusional States</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Oxford</publisher-name> <publisher-name>University</publisher-name>
<publisher-name> Press</publisher-name>; <year>1990</year>. <fpage>2010</fpage>.</citation>
</ref>
<ref id="bibr48-1049909111423094">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akechi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Uchitomi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Usage of haloperidol for delirium in cancer patients</article-title>. <source>Support Care Cancer</source>. <year>1996</year>;<volume>4</volume>(<issue>5</issue>):<fpage>390</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr49-1049909111423094">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storey</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>HH</given-names>
</name>
</person-group>. <article-title>Subcutaneous infusions for control of cancer symptoms</article-title>. <source>J Pain Symptom Manage</source> <year>1990</year>;<volume>5</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr50-1049909111423094">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ripamonti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Twycross</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baines</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer</article-title>. <source>Support Care Cancer</source> <year>2001</year>;<volume>9</volume>(<issue>4</issue>):<fpage>223</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr51-1049909111423094">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rousseau</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Palliative sedation in the management of refractory symptoms</article-title>. <source>J Support Oncol</source>. <volume>2</volume>(<issue>2</issue>):<fpage>181</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>